Pipeline - Senti Bio
Product Candidates: Multiple iPSC Cell Therapy Programs. Target: Undisclosed. Application: Regenerative medicine
Senti Bio Highlights Initial Gene Circuit Data From Collaborations …
2023年5月20日 · Showcases gene circuit application in iPSC-derived cells in collaboration with BlueRock Therapeutics. Massively parallel and systematic engineering platform for highly …
Senti Bio and BlueRock Therapeutics Enter Collaboration to …
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology …
4周使关键指标下降超90%的基因编辑疗法；80%患者应答持续达1 …
2024年12月8日 · senti-202是一种逻辑门控的现货型car-nk细胞疗法候选产品，旨在选择性靶向并清除表达cd33和/或flt3的血液恶性肿瘤，如aml和骨髓增生异常综合症（mds），同时避免杀 …
2023 AACR大会：下一代细胞治疗的苗头在哪？ - 健康界
2023年4月21日 · 除了老牌企业Century Therapeutics再次公布结果，对其iPSC衍生的细胞治疗平台进行了概念验证外，另一家企业Senti Bio则将逻辑门控技术与CAR-NK疗法相结合，展现了 …
Senti Bio Announces Pipeline Prioritization to Focus on Logic …
2023年1月27日 · Our lead product candidate is SENTI-202 for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as AML and MDS. Additionally, our SENTI-401 …
Senti Bio and BlueRock Therapeutics Enter Collaboration to
2021年5月26日 · BlueRock Therapeutics plans to apply Senti Bio’s Smart Sensor and Regulator Dial gene circuit technology platform towards the goal of developing highly sophisticated …
as well as with Bayer and BlueRock around iPSC cell engineering. On Slide 6, I'm happy to introduce SENTI-202 which is a potentially first-in-class, selective, off-the-shelf cell therapy …
Senti Bio Highlights Initial Gene Circuit Data From - GlobeNewswire
2023年5月20日 · Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages...
Senti Bio’s Internal Programs Focus on Oncology, Partnering to Support Non-Oncology Indications AML: Acute myeloid leukemia; MDS: Myelodysplastic syndrome; HCC: …
- 某些结果已被删除